Related Experiment Video
Updated: Aug 16, 2025
A Spheroid Killing Assay by CAR T Cells
Published on: December 12, 2018
[CAR-T cells development in solid tumors]
Nathan El Ghazzi1, Antoine Italiano2, Jacques-Olivier Bay1
1CHU Gabriel Montpied, service d'oncologie médicale, Clermont-Ferrand, France; Université Clermont Auvergne, Clermont-Ferrand, France.
Abstract:
CAR-T cells have produced very promising results in the field of onco-hematology and have been rapidly approved for marketing in France for several years now. In solid tumors, current results are more disappointing. Indeed, many hurdles come in the way. Tumor vascularization, the strongly immunosuppressive microenvironment, the loss of the target antigen as well as T cell exhaustion are part of the explanation of those results. Hence many researchers are working to develop strategies to counteract these resistance mechanisms. Arming CAR-T cells with BiTEs, with immune checkpoint inhibitors or with interleukins seem to be effective ways to improve antitumor efficacy. Other strategies including vaccines association or local delivery of the CAR-T cells look very promising. Many Phase I studies are investigating these new strategies and are expected to improve the previous results obtained to date in this area.
Insights
Chimeric antigen receptor T-cell (CAR-T) therapies show promise in blood cancers but face challenges in solid tumors. Researchers are developing new strategies to overcome resistance and improve CAR-T cell efficacy against solid tumors.
Area of Science:
- Oncology
- Immunotherapy
- Cellular Therapy
Context:
- CAR-T cell therapy has revolutionized onco-hematology with successful marketing approvals.
- Significant challenges hinder CAR-T efficacy in solid tumors, including tumor vascularization and immunosuppressive microenvironments.
- T cell exhaustion and antigen loss are key resistance mechanisms limiting CAR-T cell effectiveness in solid tumors.
Purpose:
- To explore strategies for overcoming CAR-T cell resistance mechanisms in solid tumors.
- To review novel approaches aimed at enhancing CAR-T cell antitumor activity.
- To summarize ongoing research and clinical trials investigating improved CAR-T cell therapies for solid malignancies.
Summary:
- CAR-T cells demonstrate limited success in solid tumors due to biological hurdles like immunosuppression and T cell exhaustion.
- Strategies such as arming CAR-T cells with bispecific T-cell engagers (BiTEs), immune checkpoint inhibitors, or interleukins are being investigated.
- Combination therapies, including vaccine associations and localized CAR-T cell delivery, show potential for improved outcomes.
Impact:
- These advancements aim to translate the success of CAR-T therapy from hematologic malignancies to solid tumors.
- Ongoing Phase I studies are crucial for validating these novel strategies and improving patient responses.
- The development of enhanced CAR-T cell therapies holds significant promise for treating previously intractable solid tumors.
